Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Presentation (November 2024)
16 slides from Faron Pharmaceuticals Oy's investor presentation, November 2024
Slide 1: Activate Your Body to Deactivate Cancer
ACTIVATE YOUR BODY TO DEACTIVATE CANCER Join us in transforming blood cancer care 1 CONFIDENTIAL
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG K
Slide 3: Harnessing the Power of Macrophages to Conquer Immune Resistance
Harnessing the Power of Macrophages to Conquer Immune Resistance CLEVER approach to sensitizing treatment resistant cancers to standard of care Clever-1 is a master immunosuppressive receptor on macrophages allowing tumor growth and metastases Bexmarilimab (Bex) is a humanized monoclonal high affini
Slide 4: Pipeline overview
Pipeline overview Harnessing the power of the immune system Treatment Indication(s) Phase of Development Anticipated Key Milestones Preclinical Phase 1 Phase 2 Phase 3 Single-Agent Advanced solid tumors ▪ Completed. Bex can modulate the TME Bexmarilimab FARON SPONSORED MATINS (First in Human, single
Slide 5: Blood cancers, including MDS, are a significant global challenge
Blood cancers, including MDS, are a significant global challenge with poor prognosis for many patients and high cost to the healthcare system Globally Every ~1.3 million ~25 seconds ~30% new patients are diagnosed with someone in the world is diagnosed of blood cancer patients still do not blood can
Slide 6: Treatment resistant MDS is one of the deadliest of all cancers
Treatment resistant MDS is one of the deadliest of all cancers Myelodysplastic syndrome that has not responded or relapsed on standard care (r/r MDS) Significant amount of patients No viable treatment options for r/r MDS1) ~180-510K people globally live with MDS 50% of patients will not respond to H
Slide 7: The market opportunity in r/r MDS
The market opportunity in r/r MDS MDS represents a significant growing market with an un-tapped area especially in r/r MDS MDS market growth r/r MDS patient journey2) Estimated worldwide indication sales by year (USDbn)1) 180-510k MDS Patients in the US & EU3) ! 50% 50% As a new, well tolerated effe
Slide 8: Clever-1 is highly expressed by malignant cells
Clever-1 is highly expressed by malignant cells leukemic cells B-ALL BCL/TCL Patients with higher-risk MDS, in whom azacitidine (HMA-agent) treatment T- ALL MM has failed, have a poor MDS CML prognosis and low AML probability of response to FAB M3 AML T-Lymphoid salvage treatments CLL Low Clever-1 M
Slide 9: Our CLEVER-1 solution
Our CLEVER-1 solution A novel mechanism of action that activates your immune system and deactivates cancer ACTIVATE DEACTIVATE Bexmarilimab targets the CLEVER-1 Bexmarilimab deactivates the receptor on immune cells defense mechanisms of leukemic (monocytes), reprogramming them cancer cells. This ena
Slide 10: Positive results continued in on-going Phase 2 trial
Positive results continued in on-going Phase 2 trial Faron is working to extend life for r/r MDS patients ✓ Majority of responses are deep and durable1) 9 out of 14 r/r MDS patients have achieved remission allowing three patients to undergo a stem cell transplant1) allo-HSCT * allo-HSCT Transformed
Slide 11: Bexmarilimab has proven that it can overcome treatment resistance
Bexmarilimab has proven that it can overcome treatment resistance Phase 1 & 2 trial results compared to available options in r/r MDS Objective Response Rate (ORR)4) Current options Bexmarilimab 79% Old, toxic and poorly 1 effective treatments1) 1 Well tolerated Overall median survival Overall median
Slide 12: Overall Clinical Development Plan for HR MDS per FDA Guidance
Overall Clinical Development Plan for HR MDS per FDA Guidance 2024 2025 2026 2027 H1 H2 H1 H2 H1 H2 H1 H2 Phase II Phase 3 & BLA P2 Interim Full P1/P2 Full P1/P2 Readout Readout Survival Analysis Phase 2 - RDE r/r MDS r/r MDS Accelerated MDS FDA FDA EOP2 FDA Pre-AA Approval r/r MDS AA Fast Track Mee
Slide 13: Faron as a Business Case
Faron as a Business Case Value creation opportunity moving from Phase 2 to 3 and accelerated approval Acquisition values of biotech companies Faron as an investment opportunity Mean acquisition values at different stages of company’s lead product (USDm)1) ✓ Clear market opportunity with limited comp
Slide 14: Outlook
Outlook Value creation opportunity with full Phase 2 read-outs (response rate, duration of response and survival), regulatory interactions, partnering and combo data with anti-PD-1 ➢ Dec 2024 Phase II Interim readout at ASH ➢ Phase II enrollment completed by Jan 2025 ➢ End of Q1 2025 full Phase 2 re
Slide 15: Leadership focused on delivering value to patients and investors
Leadership focused on delivering value to patients and investors Management Team Juho Jalkanen, MD, PhD, MSc Maija Hollmén, PhD Yrjö Wichmann, MSc Petri Bono, MD, PhD Founder & CEO Founder & CSO CFO CMO Boston, MA / Turku, Finland 24 2007 Global Headquarters Employees Year Founded 15 NON-CONFIDENTIA
Slide 16: Advisors and board add further depth and experience
Advisors and board add further depth and experience Scientific Advisors Tom Powles, MBBS, Amer Zeidan, MD, MBBS, Toni Choueiri, MD, FASCO Naval G. Daver, MD Mika Kontro, MD, PhD Cristophe Massard, MD, PhD MRCP, MD MHS Professor Professor Professor Professor Adjunct Professor Professor Board of Direc
Faron Pharmaceuticals — Investor Presentation (November 2024) on 6ix